Abstracts tagged "immunology"

Abstract Number: 2184 • ACR Convergence 2022
CaMK4 Controls the Humoral Response via the T Follicular Helper Compartment and Regulates Autoimmunity
Marc Scherlinger¹, Hao Li², Wenliang Pan², Maria Tsokos¹ and George Tsokos², ¹BIDMC Harvard University, Boston, MA, ²Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a dysregulated T cell compartment and production of autoantibodies leading to organ damage. We previously identified that…
Abstract Number: 0218 • ACR Convergence 2022
A Web-based Education Program Improves Health Care Provider Knowledge for the Care of Cancer Patients Receiving Immunotherapy Who Develop Rheumatic Immune-related Complications, and Those with Pre-existing Rheumatic Disease: An Initiative of CanRIO
Janet Roberts¹, Keith Lau², Daniel Ennis³, Marie Hudson⁴, Shahin Jamal³, Steven Katz² and Carrie Ye², ¹Dalhousie University, Halifax, NS, Canada, ²University of Alberta, Edmonton, AB, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴McGill University, Montréal, QC, Canada
Background/Purpose: Immunotherapy has revolutionized the treatment of many advanced stage malignancies. These agents harness the immune system to fight cancer. However, use of these agents…
Abstract Number: 0633 • ACR Convergence 2022
Identification of Systemic Lupus Erythematosus Endotypes by Analysis of Inflammatory and Immunologic Gene Expression Signatures
Erika Hubbard¹, Prathyusha Bachali², Kathryn Kingsmore Allison¹, Yisha He¹, Michelle Catalina³, Amrie Grammer⁴ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²AMPEL BioSolutions, Redmond, WA, ³AMPEL BioSolutions, Harvard, MA, ⁴AMPEL LLC, Charlottesville, VA
Background/Purpose: One of the hallmarks of SLE is clinical and molecular heterogeneity. Recent work has leveraged next-generation sequencing techniques to identify molecular signatures characteristic of…
Abstract Number: 0789 • ACR Convergence 2022
The Persistence of Anti-Spike Antibodies Following Two SARS-CoV-2 Vaccine Doses in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy Compared to Healthy Controls: A Prospective Cohort Study
Ingrid Egeland Christensen¹, Ingrid Jyssum¹, Anne Therese Tveter¹, Joe Sexton¹, Siri Mjaaland², Grete Birkeland Kro³, Tore K. Kvien¹, David Warren³, Jørgen Jahnsen⁴, Ludvig A. Munthe³, Espen Haavardsholm¹, Gunnveig Grødeland³, Kristin Kaasen Jørgensen⁴, Silje Watterdal Syversen¹, Guro Løvik Goll¹ and Sella Aarrestad Provan¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Norwegian Institute of Public Health, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Akershus University Hospital, Oslo, Norway
Background/Purpose: The durability of vaccine-induced humoral immunity against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy is not well characterized. The aim…
Abstract Number: 1548 • ACR Convergence 2022
Immune Cells Are Highly Disturbed in Polymyalgia Rheumatica Patients
Guillermo CARVAJAL ALEGRIA¹, Sara Boukhlal², Sophie Hillion³, Pierre Pochard³, Emmanuelle Porchet³, Alain Saraux⁴, sandrine jousse joulin⁵, Thierry MARHADOUR⁶, Dewi Guellec³, Divi CORNEC⁷ and Valerie Devauchelle², ¹CHRU de Tours, Tours, France, ²Université de Bretagne Occidentale, Brest, France, ³CHRU de Brest, Brest, France, ⁴CHU Brest, Brest, France, ⁵Roche, Brest, France, ⁶CHU Cavale Blanche, Brest, France, ⁷CHRU Brest, Brest, France
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory disease. But it's pathophysiology and the impact of the treatments on immune cells are poorly known. Our objectives…
Abstract Number: 1736 • ACR Convergence 2022
IL-23 Signaling Induces Autoimmune Disease Genes in Mucosal-Associated Invariant T Cells
Tharshana Stephen¹, Ambre Dangien¹, Claire Leloup¹, Ikram Mezghiche¹, Laetitia Camard¹, Hanan Yahia-Cherbal¹, Vincent Guillemot², Natalia Pietrosemoli¹, Hélène Lopez-Maestre¹, Julie Marsande¹, Milena Hasan¹, Dan Cua³, Anne Fourie⁴, Carrie Greving⁵, Raphaelle Parker⁶, Barbara Joyce Shaikh⁷, Bénédicte Oulès⁸, Sarah Guégan⁸, Sélim Aractingi⁸, Elisabetta Bianchi¹ and Lars Rogge¹, ¹Institut Pasteur, Paris, France, ²Institut Pasteur, Paris, Ile-de-France, France, ³Janssen Research and Development, LLC, Spring House, PA, ⁴Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, CA, ⁵Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, ⁶Janssen Research & Development, Janssen-Cilag, Paris, France, ⁷Janssen Research & Development, LLC, San Diego, CA, ⁸Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Genome-wide association studies and mouse models of autoimmune disease have demonstrated an important role of the IL-23 signaling pathway in the pathogenesis of axial…
Abstract Number: 2185 • ACR Convergence 2022
Development of a Novel Regulatory T Cell-Based Therapy for Patients with Rheumatoid Arthritis
Anne-Renee van der Vuurst de Vries¹, Kathryn Hooper¹, Jonathan Graf², Katie Tuckwell¹ and Joshua Beilke¹, ¹Sonoma Biotherapeutics, South San Francisco, CA, ²Ucsf, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory condition with persistent unmet medical need despite significant treatment advances. The pathogenesis of RA is initiated…
Abstract Number: 0261 • ACR Convergence 2022
Machine Learning and Computational Pathology Can Reveal Synovial Pathotypes in Mice and Humans
Richard Bell¹, Matthew Brendel², Justin Xiang³, AMP RA/SLE Consortium¹, Edward DiCarlo¹, Jennifer Anolik⁴, Laura Donlin¹, Dana Orange⁵, Edward Schwarz⁴, Lionel Ivashkiv¹ and Fei Wang², ¹Hospital for Special Surgery, New York, NY, ²Weil Cornell Medical College, New York, NY, ³Horace Grant High School, New York, NY, ⁴University of Rochester Medical Center, Rochester, NY, ⁵The Rockefeller University, New York, NY
Background/Purpose: Synovial pathotyping is a critical step in understanding the etiology of inflammatory arthritis as different pathotypes have differential response to therapy. Determining these pathotypes…
Abstract Number: 0646 • ACR Convergence 2022
Modulation of Type I IFN Production and Regulatory T Cells by the PKGI/ROCK Signaling Pathway
Ruth Fernandez Ruiz¹, Ilona Nln², Jacqueline Paredes² and Timothy Niewold², ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York, NY
Background/Purpose: IFNα is a pathogenic factor in SLE. The PRKG1 rs7897633 variant has been previously identified as the top hit in European ancestry patients with…
Abstract Number: 0791 • ACR Convergence 2022
Immunogenicity and Safety of a Three-dose SARS-CoV-2 Vaccination Strategy in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy
Ingrid Jyssum¹, Anne Therese Tveter¹, Joe Sexton¹, Ingrid Egeland Christensen¹, Siri Mjaaland², David Warren³, Tore K. kvien¹, Kristin Hammersbøen Bjørlykke⁴, Grete Birkeland Kro³, Jørgen Jahnsen⁴, Ludvig A. Munthe³, Espen Haavardsholm¹, Gunnveig Grødeland³, Sella Aarrestad Provan¹, Kristin Kaasen Jørgensen⁴, Guro Goll¹ and Silje Watterdal Syversen¹, ¹Diakonhjemmet Hospital, OSLO, Norway, ²Norwegian Institute of Public Health, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Akershus University Hospital, Oslo, Norway
Background/Purpose: Humoral vaccine responses to SARS-Cov-2 vaccines are impaired and short lasting in patients with immune-mediated inflammatory diseases (IMIDs). Concerns have been raised regarding their…
Abstract Number: 1565 • ACR Convergence 2022
Dissection of Ocular and Peripheral Blood Immune Phenotypes Suggests Preferential Transmigration of CD16+ Monocytes to Effector Sites in Behçet’s Disease
Yesim Ozguler¹, Ziyan Lin², Ann Cavers³, gulen Hatemi⁴, Olivier Manches⁵ and Johannes Nowatzky³, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, New York, NY, ²NYU Grossman School of Medicine, NYU Langone Applied Informatics Laboratories, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁵Recherche et Développement, Immunobiology and Immunotherapy in Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France
Background/Purpose: Cellular immunity of Behçet's Disease (BD) remains poorly understood. Previous work has provided clues pointing to most innate and adaptive immune cell types in…
Abstract Number: 1742 • ACR Convergence 2022
Shared Epitope Allomorphs Directly Influence Antigen-specific T-cell Responses in RA
Ravi Kumar¹, Anatoly Dubnovitsky¹, Christina Gerstner¹, Niyaz Yoosuf², Sara Turcinov¹, Sanjay Boddul¹, Fredrik Wermeling¹, Lars Klareskog¹, Leonid Padyukov¹ and vivianne malmström¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Bioinvent International AB, Lund, Sweden
Background/Purpose: The products of rheumatoid arthritis (RA)-associated MHC class II risk alleles HLA-DRB1*04:01 and *04:04 (DR4) differ only by two amino acids in the peptide…
Abstract Number: 2186 • ACR Convergence 2022
Cellular and Humoral Responses Following SARS-CoV-2 mRNA Vaccination in Patients on PD-1 Immunotherapy with irAEs
Sokratis Apostolidis¹, Paulina Coutifaris², Mark Painter³, Ajinkya Pattekar², Rishi Goel¹, divij mathew², Wenzhao Meng², Kevin Wang², Bria Fulmer², Angela Corrigan², Kendall Lundgreen², Elizabeth Drapeau², Derek Oldridge², Josephine Giles², Amy Baxter², Sasikanth Manne², Michelle Mckeague², Ahron Flowers², Oliva Kuthuru², Sherea Long², Jeanette Dougherty², Sigrid Gouma², Justine Williams², Maura McLaughlin², Sharon Adamski², Alba Grifoni⁴, Daniela Weiskopf⁴, Alessandro Sette⁴, Scott Hensley², Paul Bates², Eline Luning Prak¹, Laura Vella², Giorgos Karakousis², Ravi Amaravadi², Suzanne McGettigan², Kristin Kreider², Tara Mitchell², Allison Greenplate², Lynn Schuchter², Alexander Huang² and E. John Wherry¹, ¹University of Pennsylvania, Philadelphia, PA, ²UPenn, Philadelphia, ³UPenn, Philadelphia, PA, ⁴LJI, La Jolla
Background/Purpose: Patients with cancer exhibit increased mortality from SARS-CoV-2 infection compared to the general population. SARS-CoV-2 mRNA vaccination in healthy individuals generates effective and long-lasting…
Abstract Number: 0300 • ACR Convergence 2022
Exposure-Response Analyses of Upadacitinib Effects on Plasma Biomarkers in Rheumatoid Arthritis Patients
Yuli Qian¹, Fang Cai², Thierry Sornasse³, Jie Shen¹, Heidi Camp⁴ and Mohamed-Eslam Mohamed¹, ¹AbbVie, Inc., North Chicago, IL, ²AbbVie, Redwood City, CA, ³AbbVie, South San Francisco, CA, ⁴Abbvie, Winnetka, IL
Background/Purpose: Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor approved for the treatment of moderately-to-severely active rheumatoid arthritis (RA). Previous investigations demonstrated UPA modulates…
Abstract Number: 0648 • ACR Convergence 2022
Pathogenic Anti-C1q Antibodies Potentiate Activation of the Classical Complement Pathway in a Subset of Lupus Nephritis Patients
Edmund Chang¹, Julian Low², Ellen Cahir-McFarland², Henk-Andre Kroon², Yaisa Andrews-Zwilling², Ted Yednock² and Ann Mongan², ¹Annexon Biosciences, Brisbane, CA, ²Annexon Biosciences, South San Francisco, CA
Background/Purpose: In LN, excess immune complexes lead to nephrotic deposition of C1q and C4d, the latter of which has been correlated with circulating C4d and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].